Cowen raised the price target for the BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) stock to “an Outperform”. The rating was released on March 01, 2021. The stock was upgraded by Barclays, who disclosed in a research note on May 05, 2020, from Equal Weight to Overweight and set the price objective to $7. In their research brief published November 15, 2019, BofA/Merrill analysts upgraded the BioCryst Pharmaceuticals Inc. stock from Neutral to Buy with a price target of $4.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.34 during the last quarter as opposed to a consensus estimate of -$0.25, which indicates the company missed its estimate by -$0.09, which implies that the company surprised the market by -36.00%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2021) is -$0.27. This is an average of 11 analysts’ earnings, where the high earnings per share estimate is -$0.22 and the low earnings per share estimate is -$0.31. According to 9 analyst estimates, an average revenue estimate of $8.89M is projected for the current quarter with a high revenue estimate of $22M and a low estimate of $1M.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) dipped -4.00% to close Friday’s market session at $11.64, lower as compared to yesterday’s close. The stock price fluctuated between $11.54 and $12.38 throughout the trading session with the volume trading being 3506227 shares, which represented a significant variation when compared to the three months average volume of 6.63 million shares. The firm’s stock price fluctuated -4.08% within the last five trades and 14.41% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 220.52% in the last 6 months and 36.56% was added to its value over the previous 3 months. BCRX stock is trading at a margin of 5.43%, 2.38% and 65.40% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, BCRX deals in the Healthcare domain. The stock is trading -18.29 percent below its 52-week high and 252.58 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 148.19. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does BioCryst Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $2.15 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 120.96 that mirrors the cost to be found for sales by the market.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.80 percent of BioCryst Pharmaceuticals Inc. shares are owned by insiders, and 68.60 percent are held by financial institutions. Sheridan William P, the Senior VP – CMO at BioCryst Pharmaceuticals Inc. (BCRX) has sold 41,250 shares of firm on Feb 22 at a price of $11.57 against the total amount of $0.48 million. In another inside trade, Stonehouse Jon P, President & CEO of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) sold 134,278 shares of the firm on Dec 15 for a total worth of $1.12 million at a price of $8.32. An inside trade which took place on Dec 11, Senior VP, Chief Legal Officer of BioCryst Pharmaceuticals Inc. Barnes Alane P sold 13,741 shares of firm against total price of $0.11 million at the cost of $7.96 per share.